

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378]**Draft stakeholder list of consultees and commentators**

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Janssen-Cilag (abiraterone) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Black Health Agency for Equality Bob Champion Cancer Trust Cancer Black Care Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Orchid PCaSO - Prostate Cancer Network Pelican Cancer Foundation Prost8 Prostate Cancer Research Prostate Cancer UK Prostate Matters UK South Asian Health Foundation Specialised Healthcare Alliance Tackle Prostate Cancer Tenovus Cancer Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> Association of Cancer Physicians British Geriatrics Society British Oncology Pharmacy Association British Psychosocial Oncology Society Cancer Research UK Prostate Cancer Advisory Group Royal College of General Practitioners Royal College of Nursing 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> Accord (docetaxel, bicalutamide) AstraZeneca UK (bicalutamide, goserelin) Dr Reddy's (docetaxel) Hospira (docetaxel) Ipsen (triptorelin) Medac UK (docetaxel) Orion Pharma UK (histrelin) Sanofi (docetaxel) Seacross (docetaxel) Sunpharma (bicalutamide) Takeda UK (leuprorelin) Zentiva (bicalutamide)

National Institute for Health and Care Excellence

Draft stakeholder list for the proposed technology appraisal of Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of

TA721) [ID6378] Issue date: April 2025

Appendix C

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • Health Technology Wales (HTW) • NHS England 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Institute for Health Research • Pro Cancer Research Fund <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.